Express News | Citigroup Upgrades Prime Medicine to Buy, Announces $10 Price Target
Express News | Prime Medicine Inc : Citigroup Raises to Buy From Neutral
Express News | Shares of 'Meme Stocks' and High-short Interest Stocks Are Trading Higher Amid a Renewed Surge in the Space After Popular Retail Trader 'Roaring Kitty' Returned to Social Media
Is Prime Medicine (NASDAQ:PRME) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew rec
Express News | Prime Medicine Inc : Guggenheim Cuts Target Price to $18 From $20
Onward and Upward: Prime Medicine's (PRME) Extended-Session Rally
In the extended session on Monday, the rally for Prime Medicine, Inc. (NASDAQ: PRME) stock persisted, with a noteworthy 5.61% surge after-hours, reaching $6.78. This surge further augmented the rise during regular trading hours, culminating at $6.42, marking a substantial 14.44% increase. The escalation in PRME stock value coincides with an imminent significant event. Executive ...
Stocks With More Than 10% Short Interest - Finviz Screener
Prime Medicine Is Maintained at Overweight by JP Morgan
Prime Medicine Is Maintained at Overweight by JP Morgan
Prime Medicine Price Target Cut to $15.00/Share From $16.00 by JP Morgan
Prime Medicine Price Target Cut to $15.00/Share From $16.00 by JP Morgan
Buy Rating Affirmed for Prime Medicine, Inc. on FDA Trial Approval and Strong Financials
Express News | JP Morgan Maintains Overweight on Prime Medicine, Lowers Price Target to $15
Prime Medicine Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 131.84% JP Morgan $16 → $15 Maintains Overweight 05/07/2024 131.84% Jefferies $23 → $15 Assumes
Prime Medicine to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
PDF Version CAMBRIDGE, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curati
Alphabet Bought Up Two Slumping Stocks
Alphabet stock has been surging, along with peers in the Magnificent Seven, and the company has increased stakes in some of its equity investments.
Prime Medicine Inc (PRME) Q1 2024 Earnings: Navigates Through Challenges With Strategic Developments
Prime Medicine | 10-Q: Quarterly report
Buy Rating Affirmed for Prime Medicine, Inc. on Robust Preclinical Data and Prime Editing Technology Prospects
Prime Medicine Q1 2024 GAAP EPS $(0.44) Beats $(0.47) Estimate
Prime Medicine (NASDAQ:PRME) reported quarterly losses of $(0.44) per share which beat the analyst consensus estimate of $(0.47) by 6.38 percent.
Prime Medicine 1Q Loss/Shr 44c >PRME
Prime Medicine 1Q Loss/Shr 44c >PRME
Prime Medicine 1Q Research and Development Expenses $37.8M >PRME
Prime Medicine 1Q Research and Development Expenses $37.8M >PRME
No Data